Gene Expression Profile for Cutaneous Melanoma, DermTech (DecisionDx®-SCC), Pigmented Lesion Assay (PLA), myPath® Melanoma, Merlin™ Test
Melanoma is a type of skin cancer that originates from pigment-producing melanocytes in the epidermis. It accounts for less than 5% of skin cancer cases but is the major cause of skin cancer deaths in the US with more than 5000 deaths annually. Cutaneous melanoma accounts for more than 90% of cases of melanoma. The clinical subtypes of cutaneous melanoma include non-chronic sun damage (non-CSD), chronic sun damage (CSD), and acral. These subtypes are characterized with different genetic profiles with distinct therapeutic implications. For instance, the non-CSD subtype was found to have the highest proportion of BRAF mutations while c-KIT mutations are mostly seen in CSD subtypes.
Use of Gene Expression Profile (GEP) testing in cutaneous melanoma can help distinguish melanoma from other pigmented lesions, and provide valuable information to evaluate prognosis, and plan the appropriate therapeutic interventions. Several GEP tests for cutaneous melanoma are now commercially available. DecisionDx Melanoma is the most widely used GEP in the US which is designed to identify the risk of recurrence or metastasis in Stage I, II and III melanoma based on the molecular profile of 31 genes (28 prognostic genes and 3 control genes). It classifies the tumors as class 1 (low risk of metastasis) and class 2 (high-risk of metastasis). myPath® Melanoma measures 23 genes that are involved in cell differentiation, cell signaling, and immune response signaling. DermTech Inc.’s Pigment Lesion Assay (PLA) is designed to detect atypical, pigmented lesions at high risk for melanoma and measures the expression of 2 oncogenes that are over-expressed in melanoma.
- As an aid in diagnosis and management of melanoma
- Determine whether to perform sentinel lymph node biopsy in patients diagnosed with stage I or II cutaneous melanoma
Negative for abnormal gene expression
Formalin-fixed, paraffin-embedded (FFPE) tissue block, Fresh/frozen tissue.
Stability
- Ambient: Indefinitely
- Refrigerated: Indefinitely
- Future Oncol. 2019;15(7):791-800. [PMID: 30453756]
- JAMA Dermatol. 2020;156(9):1004-1011. [PMID: 32725204]
- Melanoma Manag. 2019;6(4):MMT32. [PMID: 31871621]
- Oncogene. 2003;22(20):3076-80. [PMID: 12789283]
- Dermatol Clin. 2017;35(4):537-544. [PMID: 28886810]
- Mayo Clin Proc. 2016;91(8):1147-8. [PMID: 27492918]
- Clin Cancer Res. 2015;21(1):175-83. [PMID: 25564571]
- Dermatol Clin. 2017;35(4):545-550. [PMID: 28886811]
- Ann Surg Oncol. 2021 Jan 23. [PMID: 33486642]